Management reiterated its full-year revenue target of JPY460 billion and emphasized achieving JPY550 billion in FY2025. Growth is expected from the HIV franchise, global expansion of Xocova, and ...

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has today announced that the European ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Investors might want to bet on Shionogi & Co., Ltd. Unsponsored ADR (SGIOY), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

CAMBRIDGE, MA AND PITTSBURGH, PA / ACCESS Newswire / January 23, 2025 / Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whole genome sequence- (WGS-) based ...

China's National Medical Products Administration (NMPA) approved Innovent Biologics Inc.’s NDA for Dovbleron (taletrectinib), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for treating ...

Shionogi & Co. Ltd. won a $375 million project agreement from the Rapid Response Partnership Vehicle to develop its 3CL protease inhibitor, S-892216, as a long-acting injectable for COVID-19 ...

Shionogi has been awarded $375m by the US Department of Health and Human Services (HHS) to develop a long-acting therapeutic aimed at protecting vulnerable populations from Covid-19. The funding – ...

Shionogi will receive $375 million to develop a long-acting protease inhibitor designed to prevent SARS-CoV-2 infection in people who are immune compromised.